|
|
Blood, 15 October 2007, Vol. 110, No. 8, pp. 2940-2947.
Prepublished online as a Blood First Edition Paper on July 12, 2007; DOI 10.1182/blood-2007-04-086751.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Inactivation of PI3K and PI3K distorts T-cell development and causes multiple organ inflammation
Hong Ji1,
Felix Rintelen1,
Caroline Waltzinger1,
Dominique Bertschy Meier1,
Antonio Bilancio2,
Wayne Pearce2,
Emilio Hirsch3,
Matthias P. Wymann4,
Thomas Rückle1,
Montserrat Camps1,
Bart Vanhaesebroeck2,
Klaus Okkenhaug5, and
Christian Rommel1
1 Merck Serono S. A., Geneva Research Center, Geneva, Switzerland;
2 Ludwig Institute for Cancer Research, London, United Kingdom;
3 Department of Genetics, Biology and Biochemistry, University of Torino, Torino, Italy;
4 Institute of Biochemistry & Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; and
5 Laboratory of Lymphocyte Signaling and Development, The Babraham Institute, Cambridge, United Kingdom
Mice lacking both the p110 and p110 isoforms display severe impairment of thymocyte development. Here, we show that this phenotype is recapitulated in p110 –/–/p110 D910A/D910A (p110 KO D910A) mice where the p110 isoform has been inactivated by a point mutation. Moreover, we have examined the pathological consequences of the p110 deficiency, which include profound T-cell lymphopenia, T-cell and eosinophil infiltration of mucosal organs, elevated IgE levels, and a skewing toward Th2 immune responses. Using small-molecule selective inhibitors, we demonstrated that in mature T cells, p110 , but not p110 , controls Th1 and Th2 cytokine secretion. Thus, the pathology in the p110 -deficient mice is likely to be secondary to a developmental block in the thymus that leads to lymphopenia-associated inflammatory responses.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Doukas, L. Eide, K. Stebbins, A. Racanelli-Layton, L. Dellamary, M. Martin, E. Dneprovskaia, G. Noronha, R. Soll, W. Wrasidlo, et al.
Aerosolized Phosphoinositide 3-Kinase {gamma}/{delta} Inhibitor TG100-115 [3-[2,4-Diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a Therapeutic Candidate for Asthma and Chronic Obstructive Pulmonary Disease
J. Pharmacol. Exp. Ther.,
March 1, 2009;
328(3):
758 - 765.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Martin, M. D. Schwartz, S. C. Jameson, and Y. Shimizu
Selective Regulation of CD8 Effector T Cell Migration by the p110{gamma} Isoform of Phosphatidylinositol 3-Kinase
J. Immunol.,
February 15, 2008;
180(4):
2081 - 2088.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Harris, R. V. Parry, J. Westwick, and S. G. Ward
Phosphoinositide Lipid Phosphatases: Natural Regulators of Phosphoinositide 3-Kinase Signaling in T Lymphocytes
J. Biol. Chem.,
February 1, 2008;
283(5):
2465 - 2469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Garcon, D. T. Patton, J. L. Emery, E. Hirsch, R. Rottapel, T. Sasaki, and K. Okkenhaug
CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer
Blood,
February 1, 2008;
111(3):
1464 - 1471.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|